Entero Healthcare Solutions

    ENTERO
    Consumer
    ₹1,986.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹8,652 Cr

    P/E
    62.12
    Day range
    ₹1,935.80 – ₹2,018.10
    52-week range
    ₹944.00 – ₹2,137.60
    Volume
    82,992
    Open
    ₹1,979.90
    Prev close
    ₹1,966.60

    Latest results · Q2 FY27(consolidated)Revenue ₹2,087 Cr+32.9%Profit ₹61 Cr+66.0%Margin 2.9%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      Under Additional surveillance (ASM)

      The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 57 / 100

    Factor percentiles

    Value34
    Quality27
    Momentum94
    Low volatility70

    Derived metrics

    Earn. yield
    1.6%
    Graham no.
    ₹551.91
    vs Graham
    -72.2%
    ROE ÷ P/B
    1.8%
    12-1 mom.
    +38.7%
    Return / vol
    1.79
    Magic Formula
    #551
    Piotroski
    3/6
    FCF yield
    0.3%
    PEG
    0.94

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 90 in Consumer
    Largest Consumer companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Titan CompanyTITAN₹4.12 L Cr58.6723.8337.1%21.0%14.0%1.51+10.1%
    Asian PaintsASIANPAINT₹2.47 L Cr51.1411.2321.6%26.0%16.0%0.21+16.9%
    Avenue SupermartsDMART₹2.26 L Cr72.598.6012.9%17.0%7.0%0.16+17.8%
    TrentTRENT₹1.70 L Cr89.7321.7527.7%28.0%18.0%0.30+21.9%
    Lenskart SolutionsLENSKART₹1.27 L Cr162.3313.716.8%8.0%22.0%0.37+35.7%
    The Indian Hotels CompanyINDHOTEL₹1.25 L Cr56.359.2918.6%17.0%28.0%0.25+21.7%
    MeeshoMEESHO₹1.17 L Cr188.6427.61-46.6%-40.0%-6.0%0.01+34.4%
    Entero Healthcare SolutionsENTERO₹8,652 Cr62.124.818.6%10.0%5.0%0.51+32.8%
    Sector median₹10,665 Cr40.834.8313.0%15.0%12.5%0.27+19.1%

    Sector as classified in the tracked universe; medians use every tracked Consumer company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 4h ago

    Headlines about Entero Healthcare Solutions from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    60.5
    Price / Book
    4.86
    ROE (FY26)
    8.6%
    ROCE (latest year)
    10%
    Dividend yield
    0.00%

    Moving averages (NSE)

    20-day
    ₹1,734.35
    Price above
    50-day
    ₹1,734.99
    Price above
    200-day
    ₹1,349.33
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +25.9%
    Revenue YoY (Sep 2026)
    +32.8%
    Profit YoY (Sep 2026)
    +64.9%
    Operating margin
    5.0%
    Net margin
    2.9%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%3%6%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • Public
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY24FY25FY260%2.5%5%7.5%10%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    -500 Cr0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x0.5x1x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales9931,0341,0971,3011,3591,3391,4041,5711,7071,9101,9402,087
    Expenses9641,0051,0671,2581,3091,2901,3541,5091,6391,8241,8441,976
    Operating Profit2929304250495062688697111
    OPM %2.9%2.8%2.8%3.3%3.7%3.6%3.6%4%4%4.5%5%5%
    Other Income2913118765-4434
    Interest161710111010111214172123
    Depreciation67778891010151213
    Profit before tax81427353937364540586778
    Tax %16%-56%25%25%25%16%17%18%16%22%22%23%
    Net Profit72121262931303734455261
    EPS in Rs₹1.91₹4.82₹4.62₹5.43₹5.85₹5.90₹6.39₹7.26₹6.35₹6.44₹8.77₹10.46

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days67

    +17 days since Mar 2021

    Inventory Days52

    -2 days since Mar 2021

    Days Payable45

    +23 days since Mar 2021

    Cash Conversion Cycle74

    -8 days since Mar 2021

    Working Capital Days35

    -19 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services [1]

    Strengths

    • Company is expected to give good quarter
    • Company has delivered good profit growth of 57.3% CAGR over last 5 years
    • Company's working capital requirements have reduced from 49.4 days to 34.8 days

    Risks

    • Stock is trading at 4.85 times its book value
    • Though the company is reporting repeated profits, it is not paying out dividend
    • Company has a low return on equity of 6.04% over last 3 years.

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +30%
    3 Years
    +26%
    TTM
    +35%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +57%
    3 Years
    +130%
    TTM
    +29%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +83%

    Return on Equity

    10 Years
    —
    5 Years
    —
    3 Years
    +6%
    Last Year
    +7%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter52.42%52.42%52.40%52.40%0.00 pp
    FII5.14%4.03%4.36%5.76%+1.40 pp
    DII16.42%16.62%15.48%21.16%+5.68 pp
    Public26.03%26.94%27.77%20.67%-7.10 pp

    Filed with NSE for Sept 2026: promoters 52.40%, public 47.60%

    Analysts & fund holdings

    100%
    100% recommend buy
    5 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E62.1 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 11.15% (+2.18 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters52.4%
    • Foreign institutions5.8%
    • Mutual funds11.2%
    • Insurance0.0%
    • Other domestic institutions10.0%
    • Retail10.9%
    • Others9.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Invesco India Contra Fund2.20%0.98%+0.00 pp
    HDFC Balanced Advantage Fund2.18%0.18%+0.18 pp
    Bank of India Flexi Cap Fund0.75%2.06%+0.29 pp
    ICICI Pru Healthcare Fund0.55%0.66%-1.06 pp
    Edelweiss Small Cap Fund0.52%0.66%+0.66 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    Avg
    Entry point
    Good
    Red flags
    Avg

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    41.2%
    Downside volatility
    32.4%
    Worst 5% of days
    3.4%
    Average of that tail
    4.9%
    Max drawdown (1Y)
    22.7%
    Below its peak
    6.1%

    Against the market

    Beta vs Nifty 50
    0.42
    Correlation
    0.14
    Relative strength (3M)
    +37.8%
    ATR (14)
    4.6%

    Return

    Return 1M
    +25.3%
    Return 3M
    +41.7%
    Return 6M
    +66.6%
    Return 1Y
    +73.8%
    vs 200-day average
    +47.2%

    Momentum

    RSI (14)
    67.4
    MACD histogram
    32.59
    Stochastic %K
    74.9
    ADX (14)
    39.5
    +DI / −DI
    34.0 / 10.3
    Money flow index
    83.4

    Participation

    Delivery (20d avg)
    44.9%
    vs its 60-day baseline
    -3.8 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    +0.7%
    52-week position
    89 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹29 Cr
    FCF yield
    0.3%
    Cash conversion
    0.66
    Accruals ratio
    0.014
    Net debt
    ₹807 Cr
    Net debt / equity
    0.45
    EV / sales
    1.24
    PEG
    0.94
    Capex intensity
    1.0%
    Revenue CAGR
    34.4%
    Profit CAGR
    55.1%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    No dividends, splits or bonuses recorded for this company yet.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Entero Healthcare Solutions: common questions

    Answered from the figures on this page.

    Entero Healthcare Solutions last traded at ₹1,986.00 (NSE, as of 18 Nov 2026). The last session moved it up 0.99%.

    Entero Healthcare Solutions is valued at about ₹8,652 crore (NSE, as of 18 Nov 2026).

    Entero Healthcare Solutions trades at a price-to-earnings ratio of 62.12 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Entero Healthcare Solutions has traded between ₹944.00 and ₹2,137.60 over the past 52 weeks, to 18 Nov 2026. It is currently 87% of the way up that range.

    Entero Healthcare Solutions (ENTERO) is classified under Consumer on this site's screener.